Hyperhomocysteinemia and atherosclerosis

( views:80, downloads:0 )
YANG Fan()
TAN Hong-Mei()
WANG Hong()
Journal Title:
Volume 57, Issue 02, 2005
Key Word:

Abstract: Arteriosclerosis and its complications, such as heart attack and stroke, are the major causes of death in developed countries.It was believed that age, hyperlipidemia, hypertension, diabetes and smoking are common risk factors for cardiovascular disease. In addition, overwhelming clinical and epidemiological studies have identified homocysteine (Hcy) as a significant and independent risk factor for cardiovascular disease. In healthy individuals, plasma Hcy is between 5 and 10 μmol/L. One cause of severe hypehomocys-teinemia (HHcy) is the deficiency of cystathionine β-synthase (CBS), which converts Hcy to cystathionine. CBS homozygous deficiency results in severe HHcy with Hcy levels up to 100 to 500 μmol/L. Patients with severe HHcy usually present with neurological abnormalities, premature arteriosclerosis. It has been reported that lowering plasma Hcy improved endothelial dysfunction and reduced incidence of major adverse events after percutaneous coronary intervention. The mechanisms by which Hcy induces atherosclerosis are largely unknown. Several biological mechanisms have been proposed to explain cardiovascular pathological changes associated with HHcy. These include: (1) endothelial cell damage and impaired endothelial function; (2) dysregulation of cholesterol and triglyceride biosynthesis; (3) stimulation of vascular smooth muscle cell proliferation; (4) thrombosis activation and (5) activation of monocytes. Four major biochemical mechanisms have been proposed to explain the vascular pathology of Hcy. These include: (1) autooxidation through the production of reactive oxygen species; (2) hypomethylation by forming SAH, a potent inhibitor of biological transmethylations; (3) nitrosylation by binding to nitric oxide or (4) protein homocysteinylation by incorporating into protein. In summary, our studies, as well as data from other laboratories support the concept that Hcy is causally linked to atherosclerosis, and is not merely associated with the disease. Although folic acid, vitamin B12 and B6 can lower plasma Hcy levels, the long-term effects on cardiovascular disease risk are still unknown and judgments about therapeutic benefits await the findings of ongoing clinical trials.

  • [1]Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
  • [2]Willinek WA, Ludwig M, Lennarz M, Holler T, Stumpe KO.High-normal serum homocysteine concentrations are associated with an increased risk of early atherosclerotic carotid artery wall lesions in healthy subjects. J Hypertens 2000; 18: 425-430.
  • [3]Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW,Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH.Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332:286-291.
  • [4]Stampfer, MJ, Malinow MR, Willett WC, Newcomer LM,Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. Jama 1992; 268:877-881.
  • [5]Tsai JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NE, Tan LC, Haber E, Chang TH, Schlegel R, Lee ME. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996; 97:146-153.
  • [6]Wang H, Jiang X, Yang F, Chapman GB, Durante W, Sibinga NE,Schafer AI. Cyclin A transcriptional suppression is the major mechanism mediating homocysteine-induced endothelial cell growth inhibition. Blood 2002; 99:939-945.
  • [7]Wang H, Yoshizumi M, Lai K, Tsai JC, Perrella MA, Haber E,Lee ME. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272:25380-25385.
  • [8]Wang H, Jiang X, YangF, GaubatzJW, MaL, MageraMJ, Yang X, Berger PB, Durante W, Pownall HJ, Schafer AI.Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood 2003; 101:3901-3907.
  • [9]Carson N, Cusworth D, Dent C, Field C, Neill D, Westall R.Homocysteinuria: A new inborn error of metabolism associated with mental deficiency. Arch Dis Child 1962; 38:425-436.
  • [10]Mudd SH, Finkelstein JD, Irreverre F, Laster L. Homocystinuria:An enzymatic defect. Science 1964; 143:1443-1445.
  • [11]McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128.
  • [12]Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR,Eckfeldt JH, Hess DL, Davis CE. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins:the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98:204-210.
  • [13]Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther 2002;16:391-399.
  • [14]Yap S, Naughten ER, Wilcken B, Wilcken DE, Boers GH.Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy. Semin Thromb Hemost 2000; 26:335-340.
  • [15]Heijer den, M, Brouwer IA, Bos GM, Blom HJ, van der Put NM, Spaans AP, Rosendaal FR, Thomas CM, Haak HL,Wijermans PW, Gerrits WB. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998; 18:356-361.
  • [16]Righetti M, Ferrario GM, Milani S, Serbelloni P, Rosa L La,Uccellini M, Sessa A, MoatS J, Hill MH, McDowell IF, Pullin CH, Ashfield-Watt PA, Clark ZE, Whiting JM, Newcombe RG, Lewis M J, Powers HJ. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 2003; 9:I19-24.
  • [17]O'Donnell J, Perry DJ. Pharmacotherapy of hyperhomocysteinaemia in patients with thrombophilia. Expert Opin Pharmacother 2002; 3:1591-1598.
  • [18]Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H,Kooner JS. Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000; 102:2479-2483.
  • [19]Title LM, Cummings PM, Giddens K, Genest JJ Jr, Nassar Acta Physiologica Sinica, April 25, 2005, 57 (2): 103-114BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardio12000; 36:758-765.
  • [19]Title LM, Cummings PM, Giddens K, Genest JJ Jr, Nassar Acta Physiologica Sinica, April 25, 2005, 57 (2): 103-114BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardio12000; 36:758-765.
  • [20]Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B 12,and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss heart study: a randomized controlled trial. Jama 2002; 288:973-979.
  • [21]Lentz SR. Homocysteine and vascular dysfunction. Life Sci 1997; 61:1205-1215.
  • [22]Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM,Malinow MR, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996;98:24-29.
  • [23]Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY, Zhou J, Maeda N, Krisans SK, Malinow MR, Austin RC.Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001; 107:1263-1273.
  • [24]Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98:5-7.
  • [25]Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E,Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91:6369-6373.
  • [26]Zeng X, Dai J, Remick DG, Wang X. Homocysteine mediated expression and secretion of monocyte chemoattractant protein1 and interleukin-8 in human monocytes. Circ Res 2003; 93:311-320.
  • [27]Desai A, Lankford HA, Warren JS. Homocysteine augments cytokine-induced chemokine expression in human vascular smooth muscle cells: implications for atherogenesis. Inflammation 2001; 25:179-186.
  • [28]Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17:2074-2081.
  • [29]Wang G, Siow YL, OK. Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein1 expression in vascular smooth-muscle cells: a possible role for protein kinase C. Biochem J 2000; 352:817-826.
  • [30]Dalton ML, Gadson PF Jr, Wrenn RW, Rosenquist TH. Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. Faseb J 1997; 11:703-711.
  • [31]Liu G, Nellaiappan K, Kagan HM. Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. Implications for homocystinuria. J Biol Chem 1997; 272:32370-32377.
  • [32]Welch GN, Upchurch GR Jr, Loscalzo J. Homocysteine, oxidaYANG Fan et al: Hyperhomocysteinemia and Atherosclerosis tive stress, and vascular disease. Hosp Pract 1997; 32:81-82.
  • [33]Lee ME, Wang H. Homocysteine and hypomethylation. A novel link to vascular disease. Trends Cardiovasc Med 1999; 9:49-54.
  • [34]Jakubowski H. Protein N-homocysteinylation: implications for atherosclerosis. Biomed Pharmacother 2001; 55:443-447.
  • [35]Reddington M, Pusch R. Adenosine metabolism in a rat hippocampal slice preparation: incorporation into Sadenosylhomocysteine. J Neurochem 1983; 40:285-290.
  • [36]Loehrer F, Angst C, Brunner F, Haefeli W, Fowler B. Evidence for disturbed S-adenosylmethionine: S-adenosylhomocysteine ratio in patients with end-stage renal failure: a cause for disturbed methylation reactions? Nephrol Dial Transplant 1998; 13:656-661.
  • [37]Melnyk S, Pogribna M, Pogribny IP, Yi P, James SJ. Measurement of plasma and intracellular S-adenosylmethionine and Sadenosylhomocysteine utilizing coulometric electrochemical detection: alterations with plasma homocysteine and pyridoxal 5'-phosphate concentrations. Clin Chem 2000; 46:265-272.
  • [38]Caudill MA, Wang JC, Meinyk S, Pogribny IP, Jernigan S, Collins MD, Santos-Guzman J, Swendseid ME, Cogger EA, James SJ.Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl-deficient cystathionine beta-synthase heterozygous mice. J Nutr 2001; 131:2811-2818.
  • [39]Lentz SR, Malinow MR, Piegors DJ, Bhopatkar-Teredesai M,Faraci FM, Heistad DD. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys.Arterioscler Thromb Vasc Biol 1997; 17:2930-2934.
  • [40]Charpiot P, Bescond A, Augier T, Chareyre C, Fraterno M,Rolland PH, Garcon D. Hyperhomocysteinemia induces elastolysis in minipig arteries: structural consequences, arterial site specificity and effect of captopril-hydrochlorothiazide.Matrix Biol 1998; 17:559-574.
  • [41]Smith TP, Cruz CP, Brown AT, Eidt JF, Moursi MM. Folate supplementation inhibits intimal hyperplasia induced by a highhomocysteine diet in a rat carotid endarterectomy model. J Vasc Surg 2001; 34:474-481.
  • [42]Fu WY, Dudman NP, Perry MA, Wang XL. Leukocytes extravasation in acute homocysteinemic rats. Atherosclerosis 2002;161:177-183.
  • [43]Dayal S, Arning E, Bottiglieri T, Boger RH, Sigmund CD, Faraci FM, Lentz SR. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke 2004; 35:1957-1962.
  • [44]Hofmann MA, Lalla E, LuY, Gleason MR, Wolf BM, Tanji N,Ferran LJ, Jr, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001; 107:675-683.
  • [45]Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R,Malinow MR, Maeda N. Mice deficient in cystathionine betasynthase: animal models for mild and severe homocyst(e)inemia.Proc Natl Acad Sci USA 1995; 92:1585-1589.
  • [46]Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA,Trolliet M, Heydrick S, Stark R, Klings ES, Moldovan NI,Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R,Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000; 106:483-491.
  • [47]Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR,Sigmund CD, Heistad DD, Faraci FM, Lentz SR. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ Res 2001; 88:1203-1209.
  • [48]Breslow JL. Mouse models of atherosclerosis. Science 1996;272:685-688.
  • [49]Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A,Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71:343-353.
  • [50]Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258:468-471.
  • [51]Zhou J, Moller J, Danielsen CC, Bentzon J, Ravn HB, Austin R.C, Falk E. Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2001;21:1470-1476.
  • [52]Lentz SR, Piegors DJ, Fernandez JA, Erger RA, Arning E,Malinow MR, Griffin JH, Bottiglieri T, Haynes WG, Heistad DD. Effect of hyperhomocysteinemia on protein C activation and activity. Blood 2002; 100:2108-2112.
  • [53]Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis 1993; 98:1-9.
  • [54]Tabas I. Nonoxidative modifications of lipoproteins in atherogenesis. Annu Rev Nutr 1999; 19:123-139.
  • [55]Voutilainen S, Morrow JD, Roberts LJ, 2nd, Alfthan G, Alho H,Nyyssonen K, Salonen JT. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vasc Biol 1999; 19:1263-1266
  • [56]Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin:a potential biochemical link between thrombosis, atherogenesis,and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89:10193-10197.
  • [57]Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent andindependent mechanisms. J Lipid Res 1993; 34:2051-2061.
  • [58]Cordoba-Porras A, Sanchez-Quesada JL, Gonzalez-Sastre F,114Ordonez-Llanos J, Blanco-Vaca F. Susceptibility of plasma lowand high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. J Mol Med 1996; 74:771-776.
  • [59]Weiss N, Feussner A, Hailer S, Spengel FA, Keller C, Wolfram G. Influence of folic acid, pyridoxal phosphate and cobalamin on plasma homocyst(e)ine levels and the susceptibility of lowdensity lipoprotein to ex-vivo oxidation. Eur J Med Res 1999; 4:425-432.
  • [60]Pema AF, Ingrosso D, Zappia V, Galletti P, Capasso G, De Santo NG. Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J Clin Invest 1993; 91:2497-2503.
  • [61]Weisgraber KH, Innerarity TL, Mahley RW. Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J Biol Chem 1978; 253:9053-9062.
  • [62]Buton X, Mamdouh Z, Ghosh R, Du H, Kuriakose G, Beatini N, Grabowski GA, Maxfield FR, Tabas I. Unique cellular events occurring during the initial interaction of macrophages with matrix-retained or methylated aggregated low density lipoprotein (LDL). Prolonged cell-surface contact during which ldlActa Physiologica Sinica, April 25, 2005, 57 (2): 103-114cholesteryl ester hydrolysis exceeds ldl protein degradation. J Biol Chem 1999; 274:32112-32121.
  • [62]Buton X, Mamdouh Z, Ghosh R, Du H, Kuriakose G, Beatini N, Grabowski GA, Maxfield FR, Tabas I. Unique cellular events occurring during the initial interaction of macrophages with matrix-retained or methylated aggregated low density lipoprotein (LDL). Prolonged cell-surface contact during which ldlActa Physiologica Sinica, April 25, 2005, 57 (2): 103-114cholesteryl ester hydrolysis exceeds ldl protein degradation. J Biol Chem 1999; 274:32112-32121.
  • [63]Gempel KE, Gerbitz KD, Olgemoller B, Schleicher ED. Invitro carboxymethylation of low density lipoprotein alters its metabolism via the high-affinity receptor. Horm Metab Res 1993;25:250-252.
  • [64]Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979; 76:333-337.
  • [65]Chinetti G. A- 1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferatoractivated receptors. Circulation 2000; 101 (20):2411-2417
  • [66]Hirano K, Yamashita S, Nakagawa Y, Ohya T, Matsuura F,Tsukamoto K, Okamoto Y, Matsuyama A, Matsumoto K,Miyagawa J, Matsuzawa Y. Expression of human scavenger receptor class B type Ⅰ in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ Res 1999; 85:108-116.
  • [67]Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271:518-520.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn